Literature DB >> 8499150

CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery.

C A Yedema1, P Kenemans, C M Thomas, L F Massuger, T Wobbes, R Verstraeten, G J van Kamp, J Hilgers.   

Abstract

In order to assess whether CA 125 serum levels reflect the outcome of cytoreductive surgery, CA 125 antigen levels were determined prior to and after debulking surgery in 50 ovarian cancer patients and compared to CA 125 serum levels before and after surgery in a control group of 140 patients undergoing laparotomy for various malignant or benign diseases. A significant CA 125 decrease in the first post-operative week was seen in 56% of ovarian cancer patients whereas 26% remained stable and 18% showed a significant increase after surgery. Although removal of tumour had been complete in all 14 stage I-II ovarian carcinomas, only 2 of these patients showed a subsequent significant CA 125 decrease after cytoreductive surgery, while 4 patients showed a significant increase. Such increases of CA 125 following surgery were also seen in uterine carcinomas (30%), in gastrointestinal carcinomas (75%) and in patients after laparotomy for benign gynaecological diseases (23%). CA 125 pre-treatment levels were significantly lower in patients with post-operative increases than in patients with stable or decreasing CA 125 patterns. Patients with stable CA 125 levels also had lower CA 125 pretreatment levels compared to patients with a post-operative CA 125 decrease. Post-operative increases were observed for at least 2 weeks after debulking in the case of ovarian cancer. Pre-operative levels of these patients were either within the normal range or moderately elevated. Serial measurements during surgery in partial debulking showed a rapid CA 125 decline within 24 h followed by increasing CA 125 values thereafter. Our data indicate that CA 125 serum levels in the direct post-operative period do not always reflect the outcome of cytoreductive surgery. There appears to be an effect on CA 125 levels caused by the abdominal surgical procedure itself. Consequently, CA 125 levels after abdominal surgery should be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8499150     DOI: 10.1016/s0959-8049(05)80203-5

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

1.  Lights and shadows of the tumoral marker CA-125 in ovarian cancer.

Authors:  A Sánchez Muñoz; A González Martín; C Mendiola Fernández
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

2.  Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer.

Authors:  Oliver Zivanovic; Camelia S Sima; Alexia Iasonos; Katherine M Bell-McGuinn; Paul J Sabbatini; Mario M Leitao; Douglas A Levine; Ginger J Gardner; Richard R Barakat; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2009-08-07       Impact factor: 5.482

3.  A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.

Authors:  Thomas C Krivak; Chunqiao Tian; G Scott Rose; Deborah K Armstrong; G Larry Maxwell
Journal:  Gynecol Oncol       Date:  2009-07-12       Impact factor: 5.482

4.  Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Mi-Ok Lyu; Woo Young Kim; Suk-Joon Chang; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

5.  CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer.

Authors:  C Peters-Engl; A Obermair; H Heinzl; P Buxbaum; P Sevelda; M Medl
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

6.  Evaluation of leptin serum concentrations during surgery and first-line chemotherapy in primary epithelial ovarian cancer patients.

Authors:  Jacek Przemyslaw Grabowski; Anna Markowska; Janina Markowska
Journal:  Contemp Oncol (Pozn)       Date:  2014-11-05

7.  Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma.

Authors:  Zemin Li; Han Yin; Mulan Ren; Yang Shen
Journal:  Med Sci Monit       Date:  2020-09-10

8.  A Combinatorial Proteomic Biomarker Assay to Detect Ovarian Cancer in Women.

Authors:  Meredith C Henderson; Michael Silver; Sherri Borman; Quynh Tran; Elias Letsios; Rao Mulpuri; David E Reese; Judith K Wolf
Journal:  Biomark Cancer       Date:  2018-02-13

9.  Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer.

Authors:  Nienke Zwakman; Rafli van de Laar; Toon Van Gorp; Petra L M Zusterzeel; Marc P M L Snijders; Isabel Ferreira; Leon F A G Massuger; Roy F P M Kruitwagen
Journal:  J Gynecol Oncol       Date:  2016-09-12       Impact factor: 4.401

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.